Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INCB186748 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on INCB186748, a putative KRAS G12D inhibitor (Apr 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INCB186748 | INCB 186748|INCB-186748 | KRAS G12D Inhibitor 25 | Limited information is currently available on INCB186748, a putative KRAS G12D inhibitor (Apr 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06818812 | Phase I | Gemcitabine + INCB186748 + Nab-paclitaxel Fluorouracil + INCB186748 + Leucovorin + Oxaliplatin Cetuximab + INCB186748 INCB186748 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Active, not recruiting | USA | 0 |